Uliledlimab is a humanized monoclonal antibody with potent inhibitory activity against CD73, the ecto-5-nucleotidase enzyme that catalyzes the conversion of extracellular AMP to adenosine. Uliledlimab reduces extracellular adenosine production, thereby modulating immunosuppressive pathways. Uliledlimab holds significant potential for use in immuno-oncology and cancer research.
Purity:
95.00%
CAS Number:
[2378407-27-1]
Target:
cAMP|||CD73
* VAT and and shipping costs not included. Errors and price changes excepted
